Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19

Journal of Critical Care
A CortegianiS Einav

Abstract

To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for treatment or prophylaxis of COVID-19 in adult humans. MEDLINE, PubMed, EMBASE and two pre-print repositories (bioRxiv, medRxiv) were searched from inception to 8th June 2020 for RCTs and nonrandomized studies (retrospective and prospective, including single-arm, studies) addressing the use of CQ/HCQ in any dose or combination for COVID-19. Thirty-two studies were included (6 RCTs, 26 nonrandomized, 29,192 participants). Two RCTs had high risk, two 'some concerns' and two low risk of bias (Rob2). Among nonrandomized studies with comparators, nine had high risk and five moderate risk of bias (ROBINS-I). Data synthesis was not possible. Low and moderate risk of bias studies suggest that treatment of hospitalized COVID-19 with CQ/HCQ may not reduce risk of death, compared to standard care. High dose regimens or combination with macrolides may be associated with harm. Postexposure prophylaxis may not reduce the rate of infection but the quality of the evidence is low. Patients with COVID-19 should be treated with CQ/HCQ only if monitored and within the context of high quality RCTs. High quality data about efficacy/safety are urgently needed.

Citations

Jul 6, 2020·Expert Review of Clinical Immunology·Sebastian E SattuiJeffrey A Sparks
Aug 7, 2020·American Journal of Physiology. Endocrinology and Metabolism·Emile LevySchohraya Spahis
Aug 18, 2020·Critical Care Medicine·Nicole EvangelidisUNKNOWN COVID-19-Core Outcomes Set (COS) Survey Investigators
Dec 3, 2020·Tropical Medicine and Infectious Disease·Saad AlhumaidMansour Tobaiqy
Sep 6, 2020·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Ali J Marian
Nov 24, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Bianza Moise BakadiaGuang Yang
Feb 4, 2021·International Journal of General Medicine·Xiaozhou FanRahul Khanna
Dec 29, 2020·Clinical Case Reports·Massimo DonzelliAndrea Cortegiani
Apr 27, 2021·Journal of Diabetes and Its Complications·Antonio Ceriello, Francesco Prattichizzo
Oct 3, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·A J J LammersP H P Groeneveld
May 29, 2021·Annals of Global Health·Matheus Negri BoschieroFernando Augusto Lima Marson
Jun 1, 2021·Frontiers in Microbiology·Subhajit Maity, Abhik Saha
Nov 23, 2020·Research in Social & Administrative Pharmacy : RSAP·Joshua D BrownTodd M Manini
Oct 11, 2020·Journal of Hepatology·Tarik AsselahRaymond F Schinazi
Oct 9, 2021·Advances in Rheumatology·Gecilmara Salviato PileggiMarcelo Medeiros Pinheiro

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Clinical Trials Mentioned

NCT04261517
NCT04323527
NCT04315948
NCT04322123
NCT04333732
NCT04303507
NCT04334148

Software Mentioned

- I
ROBINS
Rob
PRISMA
Rob2
Robvis
NOS

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.